Following on from information provided to NICE by the company in November 2015, the appraisal of Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 732
- Referral date:
- 01 July 2014
Provisional Schedule
- Closing date for invited submissions / evidence submission::
- TBC
- 1st appraisal committee meeting::
- TBC
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Following on from information provided to NICE by the company in November 2015, the appraisal of Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 February 2017 | Note added to the project documents |
| 06 September 2016 | Note added to the project documents |
| 02 November 2015 | Suspended. This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the manufacturer of ofatumumab has informed us that they will not provide an evidence submission for this appraisal. NICE has therefore suspended this appraisal and we will provide further updates when they are available. |
| 30 December 2014 | Please note that following on from advice received from the company this appraisal has been rescheduled.Therefore, we now anticipate that the appraisal will begin during late October 2015 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early January 2016. |
For further information on our processes and methods, please see our CHTE processes and methods manual